Gentronix Expands Specialist Sales Team in US and Europe
News Feb 17, 2012
Gentronix has expanding its sales teams with the appointments of Dorothy Zelent as Director of North American Operations, and Simon Johns as European Sales Director.
Reporting to Commercial Director, Dr. Steve Beasley, the company’s latest appointments lead the commercialization efforts in their respective territories.
With an extensive background in molecular biotechnology, Dorothy Zelent has over 10 years’ experience in academic and pharmaceutical research.
A graduate of the University of Pennsylvania, she previously conducted research into diabetes drug discovery before joining GlaxoSmithKline as a senior scientist in cardiovascular drug discovery.
Dorothy also brings broad project management skills to the role from previous positions as Director of Business Development for a number of clinical research technology companies.
European Sales Director, Simon Johns, has an impressive technical background in microbiology and genetics, as well as 20+ years’ international commercial experience supporting clients in the pharmaceutical, biotechnology and chemical sectors.
With his early research activities including the development of genotoxicity imaging systems, Simon has since worked extensively within the pre-clinical toxicology sector for several major global CROs in both Europe and the US.
Dr. Steve Beasley, Commercial Director at Gentronix comments, “Both Dorothy and Simon are experienced commercial professionals with a wealth of life sciences expertise, and we welcome them to the Gentronix team. We’re sure they will both make a significant contribution to the company’s strategy of growing the business, not only through the commercialization of our proprietary technologies, but also by expanding our service provision and continuing to establish collaborations in existing and new sectors.”
SYGNIS AG Announces Completion of Relocation of its Innova Biosciences UnitNews
Move forms part of integration into SYGNIS Group.READ MORE
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
BC Platforms Announces Collaborations in Multiple Sclerosis ResearchNews
Company's technology and research platforms used to better understand genetic basis of MS.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018